# Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

Source: https://onco.cc/trials/nct07299747/  
OnCo record `nct07299747` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of VBC103 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.

## Summary

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT07299747 by VelaVigo Bio Inc, with 255 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12-01. Interventions recorded: VBC103.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07299747
- Phase: 1/2
- Setting: A Phase I/IIa Clinical Study Evaluating the Bispecific Antibody-Drug Conjugate VBC103 Targeting Nectin-4 and TROP2 in Subjects With Advanced Malignant Solid Tumors
- Sponsor: VelaVigo Bio Inc
- Enrolled: 255

## Sources

- ClinicalTrials.gov NCT07299747: https://clinicaltrials.gov/study/NCT07299747

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07299747.json